Despite Maravai LifeSciences Holdings' significant liabilities, it has net cash, indicating a light debt load. However, its pre-interest and tax loss and declining revenue raise future earnings and balance sheet health concerns.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
While Maravai LifeSciences Holdings displays a low ROE, its ability to expand net income considerably due to efficient management and high profit reinvestment is a positive sign. Current analyst forecasts suggest continued earnings growth for the company.
Analysts project a revenue dip and a reduced price target for Maravai LifeSciences Holdings. Increased investor caution may apply due to expected underperformance.
MoffettNathanson Upgrades$Zoom視頻通訊(ZM.US)$to Market Perform From Underperform, Price Target Is $85 Zoom Video Communications has an average rating of hold and price targets ranging from $65 to $105, according to analysts polled by Capital IQ. HSBC Upgrades$雪佛龍(CVX.US)$to Buy From Hold, Price Target Is $189 Chevron (CVX) has an average rating of outperform and price targets ranging from $161 to $212, according to ...
Maravai LifeSciences股票討論區
Maravai LifeSciences Holdings, Inc.(代碼:MRVI)是一家領先的生命科學公司,提供關鍵產品以支持藥物治療、診斷和新型疫苗的開發,並支持人類疾病的研究。公司在核酸合成和生物安全檢測兩大領域優勢突出。
1
落難的公主
2022年2月25日,彭博社報道稱,Sartorius AG(賽多利斯)提出以 110億美元收購Maravai LifeSciences(MRVI)。
賽多利斯是業界赫赫有名的一家通過持續收購不斷做大做強的生命科學集團公司。這個出價必然是深思熟慮的。當時MRVI董事會認爲,這個出價嚴重低估了公司價值,故而拒絕了賽多利斯的併購請求。時過境遷,此後MRVI的市值一路下跌,時至今日已經不足10億美元。
MRVI還有未來嗎?
2
產品線
1、核酸合成業務線(Nucleic Acid Production,NAP)
提供高度修飾和複雜的核酸以及相關酶用於分子診斷、疫苗和治療等領域。
清潔蓋帽技術(CleanCap®)是公司在mR...
新增數據:2022Q4及全年,2023前兩季度
2022Q4營收下滑10.4%,營業利潤下滑29.3%,淨利潤下滑31.2%,這使得2022年營收增長10.5%,營業利潤僅增長4.2%,淨利潤僅增長4.6%。
2023前兩季度營收持續下滑,造成了連續4個季度下滑,營業利潤在2季度虧損,淨利潤則在兩個季度均虧損,這使得上半年營收下滑69.6%,營業利潤轉爲虧損,淨利潤虧損0.13億。
目前市盈率6.2,市盈率TTM已經提高到17.5,目前沒有任何趨勢扭轉的跡象,平倉了結。
Zoom Video Communications has an average rating of hold and price targets ranging from $65 to $105, according to analysts polled by Capital IQ.
HSBC Upgrades $雪佛龍(CVX.US)$ to Buy From Hold, Price Target Is $189
Chevron (CVX) has an average rating of outperform and price targets ranging from $161 to $212, according to ...
4年來營收、營業利潤和淨利潤都保持高速增長,2022前三季度營收增長19%,營業利潤增長16.5%,淨利潤增長17.6%,增速有所下滑,但是依然還在增長。
近4年資產負債率從73%上升到88%後下降到了72%。
資產負債表顯示公司流動資產大幅增長達到8.4億,長期借款5.3億,佔淨資產的63%,槓桿率居中。
5年來現金流經營淨額大幅超越投資淨額,股東盈餘很多。
目前市盈率8.9,市盈率TTM 7.7,可以選擇(⭐️⭐️)
暫無評論